Jupiter Topco LLC Buys New Stake in Halozyme Therapeutics, Inc. $HALO

Jupiter Topco LLC purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 2nd quarter, Holdings Channel.com reports. The firm purchased 1,348,843 shares of the biopharmaceutical company’s stock, valued at approximately $105,570,000.

Several other large investors also recently bought and sold shares of the stock. William Blair Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth about $196,540,000. Norges Bank purchased a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $128,201,000. Voloridge Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics in the third quarter valued at approximately $77,587,000. Qube Research & Technologies Ltd purchased a new position in shares of Halozyme Therapeutics during the second quarter worth approximately $51,295,000. Finally, Assenagon Asset Management S.A. raised its position in Halozyme Therapeutics by 4,578.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 997,643 shares of the biopharmaceutical company’s stock valued at $78,086,000 after purchasing an additional 976,321 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

HALO has been the topic of several research reports. HC Wainwright raised their price objective on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Citizens Jmp upped their price target on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Finally, Morgan Stanley lowered their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $91.20.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $107.06 on Thursday. Halozyme Therapeutics, Inc. has a 1 year low of $61.22 and a 1 year high of $109.66. The company has a market capitalization of $12.15 billion, a price-to-earnings ratio of 31.96, a PEG ratio of 0.44 and a beta of 0.85. The company’s 50 day simple moving average is $85.50 and its 200 day simple moving average is $74.39. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million for the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The business’s revenue was up 47.7% on a year-over-year basis. During the same quarter last year, the firm earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,626 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares of the company’s stock, valued at $4,154,970.40. This represents a 3.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the transaction, the director owned 14,462 shares in the company, valued at approximately $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 64,103 shares of company stock worth $5,226,496 in the last 90 days. 2.50% of the stock is owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.